Reduced levels of serotonin 2A receptors underlie resistance of Egr3-deficient mice to locomotor suppression by clozapine.
The immediate-early gene early growth response 3 (Egr3) is associated with schizophrenia and expressed at reduced levels in postmortem patients' brains. We have previously reported that Egr3-deficient (Egr3(-/-)) mice display reduced sensitivity to the sedating effects of clozapine compared with wild-type (WT) littermates, paralleling the heightened tolerance of schizophrenia patients to antipsychotic side effects. In this study, we have used a pharmacological dissection approach to identify a neurotransmitter receptor defect in Egr3(-/-) mice that may mediate their resistance to the locomotor suppressive effects of clozapine. We report that this response is specific to second-generation antipsychotic agents (SGAs), as first-generation medications suppress the locomotor activity of Egr3(-/-) and WT mice to a similar degree. Further, in contrast to the leading theory that sedation by clozapine results from anti-histaminergic effects, we show that H1 histamine receptors are not responsible for this effect in C57BL/6 mice. Instead, selective serotonin 2A receptor (5HT(2A)R) antagonists ketanserin and MDL-11939 replicate the effect of SGAs, repressing the activity in WT mice at a dosage that fails to suppress the activity of Egr3(-/-) mice. Radioligand binding revealed nearly 70% reduction in 5HT(2A)R expression in the prefrontal cortex of Egr3(-/-) mice compared with controls. Egr3(-/-) mice also exhibit a decreased head-twitch response to 5HT(2A)R agonist 1-(2,5-dimethoxy 4-iodophenyl)-2-amino propane (DOI). These findings provide a mechanism to explain the reduced sensitivity of Egr3(-/-) mice to the locomotor suppressive effects of SGAs, and suggest that 5HT(2A)Rs may also contribute to the sedating properties of these medications in humans. Moreover, as the deficit in cortical 5HT(2A)R in Egr3(-/-) mice aligns with numerous studies reporting decreased 5HT(2A)R levels in the brains of schizophrenia patients, and the gene encoding the 5HT(2A)R is itself a leading schizophrenia candidate gene, these findings suggest a potential mechanism by which putative dysfunction in EGR3 in humans may influence risk for schizophrenia.
School of Life Sciences, Arizona State University, Tempe, AZ, USA.
Alison A
AA
Williams
Wendy M
WM
Ingram
Sarah
S
Levine
Jack
J
Resnik
Christy M
CM
Kamel
James R
JR
Lish
Diana I
DI
Elizalde
Scott A
SA
Janowski
Joseph
J
Shoker
Alexey
A
Kozlenkov
Javier
J
González-Maeso
Amelia L
AL
Gallitano
D000818:Animals; D003024:Clozapine / Q000494:pharmacology; D004195:Disease Models, Animal; D051776:Early Growth Response Protein 3 / Q000172:deficiency* / Q000235:genetics*; D006801:Humans; D006993:Hypnotics and Sedatives / Q000378:metabolism*; D007650:Ketanserin; D008297:Male; D051379:Mice; D008822:Mice, Transgenic; D009043:Motor Activity / Q000187:drug effects*; D010880:Piperidines; D044402:Receptor, Serotonin, 5-HT2A / Q000378:metabolism*; D012559:Schizophrenia / Q000378:metabolism; D058826:Serotonin 5-HT2 Receptor Agonists; D012702:Serotonin Antagonists / Q000494:pharmacology
C497369:Egr3 protein, mouse; D006993:Hypnotics and Sedatives; D010880:Piperidines; D044402:Receptor, Serotonin, 5-HT2A; D058826:Serotonin 5-HT2 Receptor Agonists; D012702:Serotonin Antagonists; C066169:alpha-phenyl-1-(2-phenylethyl)-4-piperidinemethanol; D051776:Early Growth Response Protein 3; D007650:Ketanserin; D003024:Clozapine